ReNeuron Group Quote more
Price: 2.90
Chg: 0.12
Chg %: 3.97%
Date: 16:52
Stem cell treatment developer ReNeuron lost an increased 7.1m in a "transformational" year to end-March but still had plenty of cash in the bank as it moves into new cell manufacturing facility and files an investigational new drug (IND) application in the US early next year.
The AIM-listed company held cash outflow from operating activities roughly flat at 6m over the period, leaving cash, cash equivalents and bank deposits at period end of 20.92m, thanks to the 23.44m net fundraising in August 2013.
Chairman Bryan Morton said it was a transformational year for the business, both operationally and financially, as its lead stem cell therapy candidate for stroke entered Phase II clinical trials and the company began clinical development of a candidate for critical limb ischaemia.
He also noted that in both cases, and earlier-than-planned, ReNeuron gained regulatory approval to use a cryopreserved variant of its lead 'CTX' stem cell product line, which gives the treatments the potential to have "significant commercial and competitive advantages".
He confirmed the move to new cell manufacturing facility in South Wales early next year was on track, "which we believe will become a major element of ReNeurons overall value proposition".
Go here to read the rest:
ReNeuron well set after 'transformational' year